Phan. (TIF)The Splenic CD4+CD25+Foxp3+ Tregs of recipient mice had been Flow cytometric analyzed at day ten soon after transplantation. A: Lymphocytes lap door; B: CD4+CD25+T cells analyzed just before CD4+ T-cell purification; C: CD4+CD25+T cells had been analyzed right after CD4+ T cells purification; D: Foxp3 analyzed within the CD4+CD25+ T-cell fraction; E: The population of CD4+CD25+Foxp3+ T cells in pCTLA4-IgG4 modified imDC recipient mice (Group II, n = 3, 26.3661.97 ) was larger than those in islet xenograft recipient mice (Group I, n = three, 7.0360.22 )and unmodified imDC recipient mice(Group IV, n = 3, 14.0262.98 )(*P,0.01); FITC, fluorescein isothiocyanate; APC, allophycocyanin; PE, phycoerythrin. (TIF)Figure S6 Figure S7 Contrast the histological of the liver and kidney in between different groups at day 5 soon after xenotransplantation. A: Hematoxylin and eosin (H E) stained liver (magnification, 6100); B, E: Expression of CTLA4-IgG4 detected in Groups II and V by immunohistochemistry (arrow) (magnification, 6100); C, D, F, G: No expression of CTLA4-IgG4 wasCTLA4-Dependent Blocked Pathway T Cell Activationdetected by immunohistochemistry in Groups III, IV and VI (magnification, 6100); H: Expression of pCTLA4-IgG4 protein in liver and kidney tissue of recipient mice detected by Western blot evaluation (n = 2).Formula of 4-Bromo-2-methylpyrimidine Western blot evaluation displaying positive expression of pCTLA4-IgG4 in liver and kidney tissue of Groups II and V, and damaging expression in Group VI.1638760-65-2 Chemscene (TIF)Figure S8 The islet xenograft survival of 4 groups (Group I, Group II, Group III and Group IV) (n = six) in 1st experiment. Xenograft survival within the pCTLA4-IgG4 modified imDC treated group (61.0064.20 days, *P,0.01) was considerably longer than that in the islet only xenograft group (7.8361.47 days), IgG4 modified imDC treated group (31.3362.07 days), and unmodified imDC treated group (32.5065.24 days). (TIF)Figure S9 The islet xenograft survival of three groups (Group V, Group VI, Group VII) (n = six) within the second experiment. Xenograft survival in the pCTLA4-IgG4 modified imDC combined with mCTLA4-Ig treated group (111.8362.71 days, **P,0.01) was significantly longer than that in the mCTLA4-Ig combined with mCTLA4-Ig treated group (21.6761.75 days), along with the pCTLA4-IgG4 modified imDC combined with Adv-IgG4 treated group (60.1761.94 days). (TIF)Author ContributionsConceived and designed the experiments: YL BW LY. Performed the experiments: MT CZ HZ. Analyzed the data: MT. Contributed reagents/ materials/analysis tools: MT CZ.PMID:24463635 Wrote the paper: MT BW.
Int. J. Exp. Path. (2014), 95, 78?ORIGINAL ARTICLEThe increased gastroprotective effect of pioglitazone in cholestatic rats: role of nitric oxide and tumour necrosis aspect alphaLeila Moezi*,, Zeinab Janahmadi*, Zahra Amirghofran, Ali Akbar Nekooeian* and Ahmad R. Dehpour?*Department of Pharmacology, College of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran, Medicinal and All-natural Solutions Chemistry Analysis Center, Shiraz University of Healthcare Sciences, Shiraz, Iran, Department of Immunology, College of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran and �Department of Pharmacology, College of Medicine, Tehran University of Healthcare Sciences, Tehran, IranINTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGYdoi: ten.1111/iep.SUMMARYThe prevalence of gastric ulcers is higher in cholestatic sufferers, however the exact mechanism of this elevated frequency remains uncertain. It has been shown that pioglitazone accelerates the healing of pre-existing gastr.
